Commercial Metrics provides a peak sale analysis for historically launched products with benchmarks by indication to better understand the commercial potential of the R&D pipeline.
CT Design provides benchmarks for trial sizes and number of trials by phase and indication. Current and historic trial programme enrolment has been used to build a machine learning model to predict future trial programme enrolment.
Market Dynamics provides time-to-peak analysis for historically launched products with benchmarks by indication, along with exclusivity impact and patent expiry assumptions.
Net Present Value tool for the creation, annotation and saving of multiple scenarios. The NPV module uses analyst consensus forecasts along with Evaluate’s algorithms for products across all major companies.
Abridged version of the NPV Detailed Methodology.
Outcomes provides comprehensive and timely analysis of clinical trial outcomes.
Predicted Peak Sales provides an independent and balanced view of asset potential that leverages machine learning to provide systematic, comprehensive coverage across all phases of the clinical pipeline to accurately predict the commercial potential of R&D assets.
Success Rates provides fully transparent Probability of Technical and Regulatory Success (PTRS) benchmarks at an industry level, and by indication, mechanism of action and technology. Product Specific PTRS (PS-PTRS) provides accurate and transparent probabilities of success at a product and indication level.
Timelines provides estimated phase progression and approval dates for products by indication.
Unmet Need provides a standardised view of the degree of unmet needs across indications using quantifiable metrics.
Volume forecast provides product volumes at the dosage form and unit for both marketed and in-development products by integrating Evaluate consensus, Omnium projected sales, and pricing.